WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix,
Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D.,
Ph.D., NeuroMetrix President and Chief Executive Officer, will
participate in the 29th Annual Meeting of The Japan Society
of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014.
The Japan Society of Diabetic Complications is a part of The Japan
Diabetes Society which was established in 1958 to promote
diabetes-related academic research and treatment programs. The
organization has over 16,000 members and works in collaboration with
other international organizations including the International Diabetes
Federation (IDF), the American Diabetes Association (ADA), and the
European Association for the Study of Diabetes (EASD). The Annual
Meeting of the Japan Society of Diabetic Complications is one of the
major events of the Japan Diabetes Society.
Dr. Gozani will attend the Diabetic Complications Meeting where he will
present a research study entitled "Association of Median and Sural Nerve
Conduction in Patients with Diabetes". This study is important because
it links clinical work for the aldose reductase inhibitor, Epalrestat, a
marketed pharmaceutical in Japan for patients with diabetic neuropathy
with the diagnostic capability of the NeuroMetrix NC-stat DPNCheck®
device for detection of peripheral neuropathies including diabetic
peripheral neuropathy (DPN). Dr Gozani will also participate in a
round-table discussion with several key opinion leaders in Japan who
focus on clinical research and treatment of patients with diabetes.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS® device for treating chronic pain, focusing on
physicians managing patients with neuropathic pain such as painful
diabetic neuropathy. The Company also markets DPNCheck®,
which is a rapid, accurate, and quantitative point-of-care test for
peripheral neuropathies such as diabetic neuropathy. This product is
used to detect neuropathies at an early stage and to guide treatment.
For more information, please visit http://www.DPNCheck.com
or http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
